Dietary factors and pancreatic cancer: The role of food bioactive compounds

Molecular Nutrition and Food Research

Volumn 55, Issue 1, 2011, Pages 58-73

  Johnson, Jodee ^a   De Mejia, Elvira Gonzalez ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Flavonoids; Food based dietary agents; Pancreatic cancer

Indexed keywords

CURCUMIN; FLAVONOID; FOLIC ACID; VITAMIN D;

ADENOCARCINOMA; CITRUS FRUIT; DIET; FEEDING BEHAVIOR; FOOD; HUMAN; METABOLISM; PANCREAS TUMOR; REVIEW; RISK FACTOR; UNITED STATES;

ADENOCARCINOMA; CITRUS; CURCUMIN; DIET; FLAVONOIDS; FOLIC ACID; FOOD; FOOD HABITS; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS; UNITED STATES; VITAMIN D;

CITRUS;

EID: 78650913831     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000420     Document Type: Review

References (115)

1. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. What you need to know about cancer of the pancreas, Available on the World Wide Web, National Cancer Institute 2010, Accessed May 2010.
3. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, AICR, Washington DC 2007.
4. Hingorani, S., in: Lowy, A., Leach, S., Philip, P. (Eds.), From Inception to Invasion: Modeling Pathways to Pancreatic Cancer - Pancreatic Cancer, Springer Science+Business Media, LLC New York 2008, pp. 159-180.
5. Dominguez-Bendala, J., in: Turksen, K. (Ed.), The Pancreas - Pancreatic Stem Cells, Humana Press, New York, NY 2009, pp. 1-10.
6. Pancreatic Cancer Detailed Guide, Available on the World Wide Web, American Cancer Society 2010, Accessed May 2010,.
7. Boland, G., Thayer, S., in: Lowy, A., Leach, S., Philip, P. (Eds.), Molecular Signaling Pathways in Pancreatic Cancer - Pancreatic Cancer, Springer Science+Business Media, LLC New York, NY 2008, pp. 181-228.
8. Hruban, R., Brune, K., Fukushima, N., Maitra, A., in: Lowy, A., Leach, S., Philip, P. (Eds.), Pancreatic Intraepithelial Neoplasia - Pancreatic Cancer, Springer Science+Business Media, LLC New York, NY 2008, pp. 41-52.
9. Kranenburg, O., The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta 2005, 1756, 81-82.
10. Shields, J., Pruitt, K., McFall, A., Shaub, A., Der, C., Understanding Ras: "it ain't over 'til it's over". Trends Cell Biol. 2000, 10, 147-154.
11. Wilson, L., Lightwood, J., Pancreatic cancer: total costs and utilization of health services. J. Surg. Oncol. 1999, 71, 171-181.
12. Singletary, K., Diet, Natural products and cancer chemoprevention. J. Nutr. 2000, 130, 465S-466S.
13. Tsao, A., Kim, E., Hong, W., Chemoprevention of cancer. CA Cancer J. Clin. 2004, 54, 150-180.
14. Schatzkin, A., Kelloff, G., Chemo- and dietary prevention of colorectal cancer. Eur. J. Cancer 1995, 31A, 1198-1204.
15. Polesel, J., Talamini, R., Negri, E., Bosetti, C. et al., Dietary habits and risk of pancreatic cancer: an Italian case-control study. Cancer Causes Control 2010, 21, 493-500.
16. Larsson, S., Hakansson, N., Naslund, I., Bergkvist, L., Wolk, A., Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 301-305.
17. Chan, J., Wang, F., Holly, F., Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol. Biomarkers Prev. 2005, 15, 2093-2097.
18. FAO Statistical Yearbook 2005-2006. Food and Agriculture Organization of the United Nations.
19. Wang, Y., Chuang, Y., Ku, Y., Quantitation of bioactive compounds in citrus fruits cultivated in Taiwan. Food Chem. 2007, 102, 1163-1171.
20. Buer, C., Imin, N., Djordjevic, M., Flavonoids: new roles for old molecules. J. Integr. Plant Biol. 2010, 52, 98-111.
21. Stewart, I., Wheaton, T., Conversion of β-citraurin to reticulataxanthin and β-apo-8'-carotenal to citranaxanthin during the isolation of carotenoids from citrus. Phytochemistry 1973, 12, 2947-2951.
22. Marti, N., Mena, P., Canovas, J., Micol, V., Saura, D., Vitamin C and the role of citrus juices as functional food. Nat. Prod. Commun. 2009, 4, 677-700.
23. Manners, G., Citrus limonoids: analysis, bioactivity, and biomedical prospects. J. Agric. Food Chem. 2007, 55, 8285-8294.
24. Tanaka, T., Kohno, H., Kawabata, K., Honjo, S. et al., in: Berhow, M., Hasegawa, S., Manners, G. (Eds.), Citrus Limonoids Obacunone and Limonin Inhibit the Development of a Precursor Lesion, Aberrant Crypt Foci, for Colon Cancer in Rats - Citrus Limonoids: Functional Chemicals in Agriculture and Food, American Chemical Society, Washington DC 2000, pp. 145-163.
25. Olsen, G., Mandel, J., Gibson, R., Wattenberg, L., Schuman, L., Nutrients and pancreatic cancer: a population-based case-control study. Cancer Causes Control 1991, 2, 291-297.
26. Silverman, D., Swanson, C., Gridley, G., Wacholder, S. et al., Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J. Natl. Cancer Inst. 1998, 90, 1710-1719.
27. Nothlings, U., Murphy, S., Wilkens, L., Henderson, B., Kolonel, L., Dietary glycemic load, added sugars, and carbohydrates as risk factors for pancreatic cancer: the multiethnic cohort study. Am. J. Clin. Nutr. 2007, 86, 1495-1501.
28. Coughlin, S., Calle, E., Patel, A., Thun, M., Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000, 11, 915-923.
29. Bueno de Mesquita, H., Masionneuve, P., Runia, S., Moerman, C., Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in the Netherlands. Int. J. Cancer 1991, 48, 540-549.
30. Stolzenberg-Solomon, R., Pietinen, P., Taylor, P., Virtamo, J., Albanes, D., Prospective study on diet and pancreatic cancer in male smokers. Am. J. Epidemiol. 2002, 155, 783-792.
31. Ji, B., Chow, W., Gridley, G., McLaughlin, J. et al., Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 885-893.
32. Lin, Y., Kikuchi, S., Tamakoshi, A., Yagyu, K. et al., Dietary habits and pancreatic cancer risk in a cohort of middle-aged and elderly Japanese. Nutr. Cancer 2006, 56, 40-49.
33. Sergeev, I., Ho, C., Li, S., Colby, J., Dushenkov, S., Apoptosis-inducing activity of hydroxylated polymethoxyflavones and polymethoxyflavones from orange peel in human breast cancer cells. Mol. Nutr. Food Res. 2007, 51, 1478-1484.
34. Jayaprakasha, G., Mandadi, K., Poulose, S., Jadegoud, Y. et al., Novel triterpenoid from Citrus aurantifolia L. possesses chemopreventive properties against human colon cancer cells. Bioorg. Med. Chem. 2008, 16, 5939-5951.
35. Tang, M., Ogawa, K., Asamoto, M., Hokaiwado, N. et al., Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci. 2007, 98, 471-477.
36. Hung, J., Hsu, Y., Ko, Y., Tsai, Y. et al., Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human non-small lung cancer cells in vitro and in vivo. Lung Cancer 2010, 68, 366-374.
37. Patil, J., Murthy, K., Jayaprakasha, G., Chetti, M., Patil, B., Bioactive compounds from Mexican lime (Citrus aurantifolia) juice induce apoptosis in human pancreatic cells. J. Agric. Food Chem. 2009, 57, 10933-10942.
38. Patil, J., Jayaprakasha, G., Murthy, K., Chetti, M., Patil, B., Characterization of Citrus aurantifolia bioactive compounds and their inhibition of pancreatic cancer cells through apoptosis. Microchem. J. 2010, 94, 108-117.
39. Ross, J., Kasum, C., Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 2002, 22, 19-34.
40. Gil-Izquierdo, A., Gil, M., Ferreres, F., Tomas-Barberan, F., In vitro availability of flavonoids and other phenolics in orange juice. J. Agric. Food Chem. 2001, 49, 1035-1041.
41. Kim, H., Mani, I., Iversen, L., Ziboh, V., Effects of naturally occurring flavonoids and bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea pigs. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58, 17-24.
42. Salabat, M., Melstrom, L., Strouch, M., Ding, X. et al., Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavonoid apigenin in pancreatic cancer cell lines. Mol. Carcinog. 2008, 47, 835-844.
43. Melstrom, L., Salabat, M., Ding, X., Milam, B. et al., Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cells. Pancreas 2008, 37, 426-431.
44. Ujiki, M., Ding, X., Salabat, M., Bentrem, D. et al., Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5, 76.
45. Lee, S., Ryu, J., Lee, K., Woo, S. et al., Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008, 259, 39-49.
46. Strouch, M., Milam, B., Melstrom, L., McGill, J. et al., The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas 2009, 38, 409-415.
47. Liu, H., Jiang, W., Xie, M., Flavonoids: recent advances as anticancer drugs. Recent Pat. Anti-Cancer Drug Discov. 2010, 5, 152-164.
48. Gibellini, L., Pinti, M., Nasi, M., Montagna, J. et al., Quercetin and cancer chemoprevention. eCam. 2010, 1-14.
49. Aghdassi, A., Phillips, P., Dudeja, V., Dhaulakhandi, D. et al., Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 2007, 67, 616-625.
50. Borska, S., Sopel, M., Chmielewska, M., Zabel, M., Dziegiel, P., Quercetin as a potential modulator of p-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010, 15, 857-870.
51. Zhang, Y., Chen, A., Li, M., Chen, C., Yao, Q., Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J. Surg. Res. 2008, 148, 17-23.
52. Shankar, S., Suthakar, G., Srivastava, R., Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front. Biosci. 2007, 12, 5039-5051.
53. Shankar, S., Ganapathy, S., Hingorani, S., Srivastava, R., EGCG inhibits growth, invasion, angiogenesis, and metastasis of pancreatic cancer. Front. Biosci. 2008, 13, 440-452.
54. Li, Y., Zhang, T., Jiang, Y., Lee, H. et al., (-)-Epigallocatechin-3-gallate inhibits hsp90 function by impairing hsp90 association with cochaperones in pancreatic cancer cell line MIA PaCa-2. Mol. Pharm. 2009, 6, 1152-1159.
55. McMillan, B., Riggs, D., Jackson, B., Cunningham, C., McFadden, D., Dietary influence on pancreatic cancer growth by catechin and inositol hexaphosphate. J. Surg. Res. 2007, 141, 115-119.
56. Mohammad, R., Banerjee, S., Li, Y., Aboukameel, A. et al., Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006, 106, 1260-1268.
57. El-Rayes, B., Ali, S., Ali, I., Philip, P. et al., Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-κB. Cancer Res. 2006, 66, 10553-10559.
58. Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M. et al., Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65, 9064-9072.
59. Banerjee, S., Zhang, Y., Wang, Z., Che, M. et al., In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer 2006, 120, 906-917.
60. L (-)-gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 2005, 31, 317-324.
61. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., Sarkar, F., Inhibition of nuclear factor κB activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int. J. Cancer 2006, 118, 1930-1936.
62. Wang, Z., Zhang, Y., Li, Y., Banerjee, S. et al., Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5, 483-493.
63. Wang, Z., Ahmad, A., Banerjee, S., Azmi, A. et al., FoxM1 is a novel target of a natural agent of pancreatic cancer. Pharm. Res. 2010, 27, 1159-1168.
64. National Institute of Health, ClinicalTrials.gov, 2010, accessed July 2010.
65. Sharma, R., Gescher, A., Steward, W., Curcumin: the story so far. Eur. J. Cancer 2005, 41, 1955-1968.
66. Ammon, H., Wahl, M., Pharmacology of Curcuma longa. Planta Med. 1991, 57, 1-7.
67. Goel, A., Kunnumakkara, A., Aggarwal, B., Curcumin as "curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75, 787-809.
68. Hua, W., Fu, Y., Liao, Y., Xia, W. et al., Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol. 2010, 637, 16-21.
69. Hilchie, A., Furlong, S., Sutton, K., Richardson, A. et al., Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr. Cancer 2010, 62, 379-389.
70. Shin, H., Kim, J., Lee, E., Kim, S., Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF - κB activations. Phytother. Res. 2010, 24, 577-582.
71. Saydmohammed, M., Joseph, D., Syed, V., Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell. Biochem. 2010, 110, 447-456.
72. Mohanty, C., Acharva, S., Mohanty, A., Dilnawaz, F., Sahoo, S., Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine 2010, 5, 433-449.
73. Sarkar, F., Banerjee, S., Li, Y., Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol. Appl. Pharmacol. 2007, 224, 326-336.
74. Li, L., Aggarwal, B., Shishodia, S., Abbruzzese, J., Kurzrock, R., Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004, 101, 2351-2362.
75. Lev-Ari, S., Starr, A., Vexler, A., Karaush, V. et al., Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 26, 2006, 4423-4430.
76. Wang, Z., Zhang, Y., Banerjee, S., Li, Y., Sarkar, F., Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106. 2503-2513.
77. Levi-Ari, S., Zinger, H., Kazanov, D., Yona, D. et al., Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother. 2005, 59, S276-S280.
78. Lev-Ari, S., Vexler, A., Starr, A., Ashkenazy-Voghera, M. et al., Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest. 2007, 25, 411-418.
79. Glienke, W., Maute, L., Wicht, J., Bergmann, L., Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells. Eur. J. Cancer 2009, 45, 874-880.
80. Glienke, W., Maute, L., Wicht, J., Bergmann, L., Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of Survivin/BIRC5 gene expression. Cancer Invest. 2010, 28, 166-171.
81. Sahu, R., Batra, S., Srivastava, S., Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 2009, 100, 1425-1433.
82. Anand, P., Kunnumakkara, A., Newman, R., Aggarwal, B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4, 807-818.
83. Bar-Sela, G., Epelbaum, R., Schaffer, M., Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 2010, 17, 190-197.
84. Epelbaum, R., Vizel, B., Bar-Sela, G., Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2008, 26, Abstract 15619.
85. Dhillon, N., Aggarwal, B., Newman, R., Wolff, R. et al., Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14, 4491-4499.
86. Shane, B., in: Alexopolous, Y., Hebberd, K., Vales, S. (Eds.), Folic Acid, Vitamin B12, and Vitamin B6 - Biochemical, Physiological, and Molecular Aspects of Human Nutrition, Saunders Elsevier, St. Louis, MO 2006, pp. 694-712.
87. Mason, J., Choi, S., Folate and carcinogenesis: developing a unifying hypothesis. Adv. Enzyme Regul. 2000, 40, 127-141.
88. Friso, S., Choi, S., Gene-nutrient interactions and DNA methylation. J. Nutr. 2002, 132, 2382S-2387S.
89. Oaks, B., Dodd, K., Meinhold, C., Jiao, L. et al., Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Clin. Nutr. 2010, 91, 449-455.
90. 12, and methionine and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 2009, 20, 1317-1325.
91. Larsson, S., Håkansson, N., Giovannucci, E., Wolk, A., Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J. Natl. Cancer Inst. 2006, 98, 407-413.
92. Li, D., Ahmed, M., Li, Y., Jiao, L. et al., 5, 10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1470-1476.
93. Stolzenberg-Solomon, R., Albanes, D., Nieto, F., Hartman, T. et al., Pancreatic cancer risk and nutrition-related methyl-group availability indicators in male smokers. J. Natl. Cancer Inst. 1999, 91, 535-541.
94. Stolzenberg-Solomon, R., Pietinen, P., Barrett, M., Taylor, P. et al., Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort male smokers. Am. J. Epidemiol. 2001, 153, 680-687.
95. Holick, M., Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80, 1678S-1688S.
96. Holick, M., in: Alexopolous, Y., Hebberd, K., Vales, S. (Eds.), Vitamin D - Biochemical, Physiological, Molecular Aspects of Human Nutrition, Saunders Elsevier St., Louis, MO 2006, pp. 863-883.
97. Garland, C., Garland, F., Gorham, E., Lipkin, M. et al., The role of vitamin D in cancer prevention. Am. J. Public Health 2006, 96, 252-261.
98. Skinner, H., Michaud, D., Giovannucci, E., Willett, W. et al., Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1688-1695.
99. Bao, Y., Ng, K., Wolpin, B., Michaud, D. et al., Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br. J. Cancer 2010, 102, 1422-1427.
100. Akhter, J., Chen, X., Bowrey, P., Bolton, E., Morris, D., Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human color cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 1997, 40, 317-321.
101. Abe-Hashimoto, J., Kikuchi, T., Matsumoto, T., Nishii, Y. et al., Antitumor effect of 22-oxa-calcitrol, a noncalcemic analogue of calcitrol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53, 2534-2537.
102. Polek, T., Murthy, S., Blutt, S., Boehm, M. et al., Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001, 49, 224-233.
103. 3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J. Steroid Biochem. Mol. Biol. 2005, 97, 173-177.
104. 2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 2008, 7, 430-436.
105. Blanke, C., Beer, T., Todd, K., Mori, M. et al., Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest. New Drugs 2009, 27, 374-378.
106. Rivera, F., Lopez-Tarruella, S., Vega-Villegas, M., Salcedo, M., Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat. Rev. 2009, 35, 335-339.
107. Wong, H., Lemoine, N., Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 412-422.
108. Stathis, A., Moore, M., Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7, 163-172.
109. O'Reilly, E., Refinement of adjuvant therapy for pancreatic cancer. J. Am. Med. Assoc. 2010, 304, 1124-1125.
110. Neoptolemos, J., Stocken, D., Bassi, C., Ghaneh, P. et al., Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. J. Am. Med. Assoc. 2010, 304, 1073-1081.
111. Qanungo, S., Das, M., Haldar, S., Basu, A., Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26, 958-967.
112. Basu, A., Haldar, S., Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. Int. J. Oncol. 2009, 34, 281-286.
113. Li, Y., Ahmed, F., Ali, S., Philip, P. et al., Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65, 6934-6942.
114. Mihaljevic, A., Michalski, C., Friess, H., Kleeff, J., Molecular mechanism of pancreatic cancer-understanding proliferation, invasion, and metastasis. Langenbecks Arch. Sur. 2010, 395, 295-308.
115. Andea, A., Sarkar, F., Adsay, V., Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 2003, 16, 996-1006.